Synergistic Integration of Positron Emission Tomography (PET) Imaging with AI, IoT, Blockchain, and Advanced Materials for Enhanced Bacterial Infection Diagnosis and Treatment
Legal Citation
Summary of the Inventive Concept
The inventive concept combines the original PET imaging agent composition with distinct technologies to create a more powerful system for diagnosing and treating bacterial infections, offering improved accuracy, efficiency, and personalized medicine.
Background and Problem Solved
The original patent disclosed a PET imaging agent composition for bacterial infection diagnosis, but it had limitations in image analysis, data security, and treatment monitoring. The new inventive concept addresses these limitations by integrating AI, IoT, blockchain, and advanced materials to provide a more comprehensive and effective solution.
Detailed Description of the Inventive Concept
The inventive concept comprises a PET imaging agent composition of 4-amino-2-[18F]-fluorobenzoic acid and 4-amino-2-[19F]-fluorobenzoic acid, combined with AI algorithms for image analysis and disease detection, IoT sensors for real-time treatment monitoring, blockchain technology for secure data storage and sharing, and novel materials for enhanced imaging sensitivity and specificity. This synergistic integration enables accurate diagnosis, personalized treatment, and efficient disease management.
Novelty and Inventive Step
The new claims introduce non-obvious combinations of the original PET imaging agent composition with AI, IoT, blockchain, and advanced materials, providing a novel and inventive solution for bacterial infection diagnosis and treatment.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT sensor configurations, blockchain architectures, or advanced materials. Variations could also include the integration of additional technologies, such as machine learning or robotics, to further enhance the system's capabilities.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the healthcare industry, particularly in the areas of infectious disease diagnosis and treatment. Target markets include hospitals, research institutions, and pharmaceutical companies, with potential applications in personalized medicine, disease surveillance, and public health management.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61B6/037 |
| A | A61 | A61K51/0402 |
| A | A61 | A61P31/04 |
| C | C07 | C07B59/001 |
| C | C07 | C07C227/12 |
| C | C07 | C07C229/60 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical imaging, radiopharmaceuticals, and diagnostic technologies, specifically focused on positron emission tomography (PET) for bacterial infection detection with expertise in molecular imaging, radiochemistry, and advanced diagnostic technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in medical imaging, radiochemistry, or biomedical engineering, possessing knowledge of PET imaging techniques, AI integration, sensor technologies, and advanced medical data management systems
Obviousness Rationale
A PHOSITA would recognize that integrating the source patent's PET imaging agent composition with emerging technologies like AI, IoT, and blockchain represents a predictable combination of known techniques in medical diagnostics. The technical elements are well-established in their respective domains, and the integration follows standard interdisciplinary approaches for enhancing medical imaging and diagnostic capabilities. The variations demonstrate systematic technological augmentation rather than non-obvious innovation.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,352 |
|---|---|
| Title | Positron imaging tomography imaging agent composition and method for bacterial infection |
| Assignee(s) | The Research Foundation for The State of University New York |